Terns Pharmaceuticals (TERN) Stock Forecast & Price Target

TERN Forecast - Frequently Asked Questions

What is Terns Pharmaceuticals' forecast for 2026?

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Terns Pharmaceuticals is $55.14, with a high forecast of $70.00 and a low forecast of $44.50.

Should I buy or sell Terns Pharmaceuticals stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last year. There is currently 1 sell rating, 10 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TERN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TERN, but not buy additional shares or sell existing shares.

Does Terns Pharmaceuticals's stock price have much upside?

According to analysts, Terns Pharmaceuticals's stock has a predicted upside of 4.13% based on their 12-month stock forecasts.

Has Terns Pharmaceuticals been upgraded or downgraded by Wall Street analysts recently?

Over the previous 90 days, Terns Pharmaceuticals's stock had 9 downgrades and 1 upgrade by analysts.

What analysts cover Terns Pharmaceuticals?

Terns Pharmaceuticals has been rated by research analysts at Barclays, BMO Capital Markets, Citizens Jmp, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Mizuho, Oppenheimer, TD Cowen, Truist Financial, Weiss Ratings, and William Blair in the past 90 days.

Do Wall Street analysts like Terns Pharmaceuticals more than its competitors?

Analysts like Terns Pharmaceuticals less than other "medical" companies. The consensus rating score for Terns Pharmaceuticals is 2.27 while the average consensus rating score for "medical" companies is 2.30. Learn more on how TERN compares to other companies.